Pulsatile Drug Delivery System (PDDS): An Overview
Arun J L
Abstract:
Pulsatile Drug Delivery systems (PDDS) are basically time-controlled drug delivery systems in which the system controls the lag time independent of environmental factors like pH, enzymes, gastro-intestinal motility. System has to be developed to deliver drug according to circadian behavior of diseases. . A pulsatile drug release, where the drug is released rapidly after a well-defined lag-time, could be advantageous for many drugs or therapies. The potential benefits of chronotherapeutics have been investigated and established for number of diseases like asthma, arthritis, cancer, diabetes, epilepsy, hypertension, ulcer, and hypercholesterolemia. This drug delivery system is programmed drug delivery system in harmonization with body clock. The pulse has to be designed in such a way that a complete and rapid dug release is achieved after the lag time. Various capsular, osmotic, single and multiple unit systems that are modulated by soluble or erodible polymer coatings, rupturable membranes are available in market. Therefore Pulsatile drug delivery is one such systems that, by delivering drug at the right time, right place and in right amounts, holds good promises of benefit to the patients suffering from chronic problems like arthritis, asthma, hypertension. These systems are beneficial for diseases showing chronopharmacological behavior. These systems also improve patient compliance by decreasing dosing frequency.
Keywords: Time Controlling, Lag Time,Pulsatile Drug Release, Circadian Rhythm, Chronotherapeutics.
References:
[1] Davis S S and Illum L, Int. J. Pharm, 1998, 176:1-8.
[2] Youan B, J. Control. Rel, 2004 98:337-353.
[3] Maroni A, Zema L, Cerea M, et al. Expt. Opinion Drug Del, 2005 2:855-871.
[4] Pozzi, Furlani, Gazzaniga, et al. Journal of Controlled Release, 1994, 31:99-108.
[5] Siegel R A and Pitt C G. J.Contrl. Rel, 1995, 33:173-188.
[6] Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current prospectives. J.Control. Release, 2009, 134:74-80.
[7] Hermida R C, Ayala D E, Calvo C, et al. Adv. Drug Del. Rev.(In press), 2007.
[8] Lemmer J. Control. Rel, 1991 16:63-74.
[9] Aaron D.L., Joseph B., Kohsaka A., Fred W.T. Sleep and circadian Rhythms: key components in the regulation of energy metabolism. FEBS. 2008; 582:142-151.
[10] Saeger H, Virley P. Pulsincap & 021 Mac226: Pulsed-Release Dosage Form. Product information from Scherer DDS, Ltd; 2004.
[11] Crison JR, Siersma PR, Amidon GL. A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy. Proceed Intern Symp Control Rel Bioact Mater. 1996; 23:51-52.
[12] Pollock-Dove C, Dong L, Wong P. A new system to deliver a delayed bolus of liquid drug formulation. Proceed Intern Symp Control Rel Bioact Mater. 2001; 28:6033.
[13] Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,318,558; 1994.
[14] Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically Driven Delivery Devices with Pulsatile Effect. US Patent No. 5209746; 1993.
[15] Magruder P R, Barclay B, Wong PSL, Theeuwes F. Composition Comprising a Therapeutic Agent and a Modulating Agent. US Patent No.4851229, 1989.
[16] Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising a Therapeutic Agent and a Modulating Agent. US Patent No. 4851229; 1989.
[17] Pozzi F, Furlani P. Orale Feste Pharmazeutische Darreichungsform Mit Programmierter Freisetzung. DE Patent No. 4122039; 1992.
[18] Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting. Int J Pharm. 1994; 111:99-102.
[19] Conte U, Colombo P, La Manna A, Gazzaniga A. A new ibuprofen pulsed release oral dosage form. Drug Dev Ind Pharm. 1989;15(14-16):2583- 2596.
[20] Conte U, Giunchedi P, Maggi L, Sangalli ME, Gazzaniga A, Colombo P, La Manna A. Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/in vivo pulsatile system. Eur J Pharm. 1992;38(6):209-212.
[21] Amidon GL, Leesman GD. Pulsatile Drug Delivery System. US Patent No. 5,229,131; 1993.
[22] Hata T, Shimazaki Y, Kagayama A, Tamura S, Ueda S. Development of a novel drug delivery system (TES): Part V: animal pharmacodynamic study and human bioavailability study. Int J Pharm. 1994;110:1-7.
[23] Chen C-M. Multiparticulate Pulsatile Drug Delivery System. US Patent No. 5,508,040; 1996.
[24] Beckert TE, Pogarell K, Hack I, Petereit H-U. Pulsed drug release with film coatings of Eudragit & Mac226; RS 30D. Proceed Int’l Symp Control Rel Bioact Mater. 1999;26:533-534.
[25] Guo X. Physicochemical and Mechanical Properties Influencing the Drug Release From Coated Dosage Forms. Doctoral Thesis. The University of Texas at Austin; 1996.
[26] Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. J Pharm Sci. 1996; 85(2):184-188.
[27] Shivram Shinde, Imran Tadwee, Sadhana Shahi. “Gastro retentive Drug Delivery System: A Review” Int. J. of Pharm. Res. & All. Sci 2012; Volume 1, Issue 1, 01-13.